Delray Beach, FL, United States of America

Joseph Collard

This inventor holds 112 USPTO granted patents and 20 published patent applications, plus 35 CIPO patents and 50 EPO patents, primarily in Gene Therapy (CPC class C12N15-113). Top assignees: Curna, Inc., Gurna, Inc., Opko Curna, LLC. Active years: 2012-2023.

USPTO Granted Patents = 112 (Patent Applications = 20)

% Patents Active = 62.5

CIPO Patents = 35 (Patent Applications = 18)

EPO Patents = 50 (Patent Applications = 59)

Average Co-Inventor Count = 2.2

ph-index = 7

Forward Citations = 197(Granted Patents)

Forward Citations (Not Self Cited) = 179(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Belray Beach, FL (US) (2014)
Delray Beach, FL (US) (2012 - 2023)

Company Filing History:

Years Active: 2012-2023

Loading Chart...

Areas of Expertise:

Tumor Suppressor Genes

Sirtuin Pathways

Lipid Metabolism

Collagen Genes

Down Syndrome

Voltage-Gated Channels

Neurotrophic Factors

Adiponectin

Reprogramming Factors

Growth Factors

Erythropoietin

Fibroblast Growth Factor

112 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11697814 - Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene (2023-07-11),

2. 11408004 - Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT) (2022-08-09),

3. 11390868 - Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity (2022-07-19),

4. 11339394 - Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene (2022-05-24),

5. 10995334 - Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2 (2021-05-04),

6. 10934546 - Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT) (2021-03-02),

7. 10876117 - Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene (2020-12-29),

8. 10793857 - Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA (2020-10-06),

9. 10696966 - Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG (2020-06-30),

10. 10604755 - Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene (2020-03-31),

11. 10583128 - Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules (2020-03-10),

12. 10563202 - Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT) (2020-02-18),

13. 10519448 - Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF (2019-12-31),

14. 10487327 - Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor (2019-11-26),

15. 10465192 - Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 (2019-11-05),

Title: Unveiling the Innovations of Joseph Collard: Pioneering Antisense Oligonucleotide Therapies

Introduction:

Joseph Collard, a brilliant inventor based in Delray Beach, FL, has made significant strides in the field of molecular biology and gene therapy. With an impressive portfolio of 112 patents, his groundbreaking work in targeting natural antisense polynucleotides has revolutionized the treatment of genetic diseases.

Latest Patents:

Collard's recent patents showcase his expertise in developing novel therapies for tumor suppressor gene and Sirtuin (SIRT) related diseases. By utilizing antisense oligonucleotides to modulate gene expression, he has paved the way for more effective treatment strategies for these debilitating conditions.

Career Highlights:

Having contributed to companies such as Curna, Inc. and Opko Curna, LLC, Collard has played a pivotal role in translating scientific discoveries into tangible medical solutions. His expertise in antisense technology has positioned him as a sought-after expert in the biotechnology industry.

Collaborations:

Collaborating closely with esteemed colleagues like Olga Khorkova Sherman and Carlos Coito, Collard has fostered a culture of innovation and collaboration. Together, they have pushed the boundaries of gene therapy, offering hope to patients grappling with genetic disorders.

Conclusion:

In conclusion, Joseph Collard's pioneering work in antisense oligonucleotide therapies underscores his commitment to revolutionizing the field of molecular medicine. His dedication to advancing the treatment of genetic diseases serves as an inspiration to aspiring inventors and researchers worldwide.